RxDoctor Payments DataLook up a doctor →

Natalie Bellini

Family · Mayfield Heights, OHNPI 1619436664

Payments from drug & device makers

$582,141in general payments, 2019–2025

Across 1,241 payments — averaging $469.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$199K
  • Abbott$181K
  • Embecta Corp.$94K
  • Sequel Med Tech, LLC$33K
  • Sanofi$13K
  • Medtronic$12K
  • plus $50K from 43 others

What the payments were for

  • Consulting fees$168,88829%
  • Speaking & faculty fees$285,16949%
  • Travel & lodging$99,37617%
  • Food & beverage$28,4825%
  • Education$1330%
  • Gifts$430%
  • Other$500%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$582,141 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$21,893
Medicare patients
99
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide283$369,638
TrulicityDulaglutide164$197,190
JardianceEmpagliflozin136$136,965
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/762$82,636
MounjaroTirzepatide61$81,698
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$43,619
Humalog Kwikpen U-100Insulin Lispro92$26,876
FarxigaDapagliflozin Propanediol27$25,449
JanuviaSitagliptin Phosphate31$25,143
Tresiba Flextouch U-100Insulin Degludec29$21,603
Levothyroxine Sodium42$20,917
Humalog Kwikpen U-200Insulin Lispro11$20,827
Tresiba Flextouch U-200Insulin Degludec23$18,037
Insulin Lispro Kwikpen U-100Insulin Lispro35$13,189
Lantus SolostarInsulin Glargine,hum.Rec.Anlog100$12,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$2,232$372,463295 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$4,727$290,301263 claims
Boehringer IngelheimJardiance$691$136,965136 claims
AstraZenecaFarxiga$149$25,44927 claims
MerckJanuvia$74$25,14331 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$20,91742 claims
BayerKerendia$310$9,00413 claims
Sanofi-aventis U.S. LLCLantus$198,710$1,67315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Mayfield Heights

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →